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of persons with painful knee effusions. Both groups made signiﬁcant gains
in peak ﬂexion and extension of the knee.
Conclusions: The physiotherapy programme tested in this trial reported
positive effects on pain and disability in OAK and improve muscle power,
but isotonic exercise are useful for improving the function of persons
with painful knee. This data suggest that isokinetic training improve joint
stability and increase the range of movement.
Therapy – Pharmacologic
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Purpose: Synovial ﬂuid hyaluronan (HA) content and molecular weight
are decreased in osteoarthritis (OA). According to a Cochrane review
intra-articular (IA) HA injection provides symptomatic relief that has slower
onset but is more sustained than corticosteroids. The mechanism for
the beneﬁt is unknown, but MRI shows a strong association between
synovitis, capsular ﬁbrosis and knee pain in OA. We determined the
effect of two HA preparations on gait, synovial and cartilage pathology in
established OA in a sheep model.
Methods: Four months after bilateral meniscectomy, sheep (n = 6/group)
received IA saline or Hyalgan® (Fidia Farmaceutici) weekly for 5 weeks
or IA HYADD4®-G (an amide derivative; Fidia) every two weeks for
3 injections. Ground reaction forces (GRF) were determined pre- and
6, 12, 16, 22 and 26 weeks post-surgery, when sheep were sacriﬁced.
Tibial cartilage damage and osteophytosis and modiﬁed Mankin and
OARSI histopathology were scored. Expression of MMP-1, -13 and -14,
ADAMTS-4 & -5 and TIMP-1, -2 & -3 in cartilage were assessed by RT-
PCR. Synovial sections were scored for intimal hyperplasia, inﬂammatory
cell inﬁltrate, vascularity and sub-intimal ﬁbrosis and intimal cell number
and depth of ﬁbrosis (mm) were quantiﬁed. Pro-ﬁbrotic and inﬂammatory
factors (TGFb, CTGF, HSP47, CD44, TNF, iNOS) were immunolocalized
in synovium. HA synthesis by isolated synovial ﬁbroblasts was quantiﬁed.
Results: OA reduced all GRF parameters (p< 0.01) and abolished
the normal two-peak vector. GRF were partially restored by both HA
preparations: Hyalgan® increased peak vertical force at 6 weeks, whilst
HYADD®4-G increased vertical impulse at all times. Both HAs restored
a two-peak composite force vector at 6 weeks. OA increased gross
cartilage damage and osteophytosis (p< 0.001), and modiﬁed Mankin
and OARSI histopathology scores (p< 0.005), with no effect of either HA.
ADAMTS-5, MMP-1 and MMP-13 mRNA were increased in OA cartilage
versus non-operated controls (NOC). Hyalgan® did not change cartilage
gene expression while HYADD4®-G decreased MMP-13 and TIMP-1.
Subintimal ﬁbrosis, vascularity, aggregate score, intimal cell numbers
and depth of ﬁbrosis were higher in OA synovia versus NOC (p< 0.01)
but inﬂammatory cells did not increase. Both HAs decreased vascularity
(p< 0.03) while intimal hyperplasia was only reduced by HYADD4®-G
(p = 0.03). Fibrosis depth was decreased by Hyalgan® (p = 0.03). Staining
for CTGF, iNOS and CD44 increased in OA synovium but were not altered
by either HA. HA synthesis was increased only in cells from HYADD4®-G
treated joints (p = 0.04).
Conclusions: GRF following meniscectomy in sheep mimic data for
human meniscectomy and OA. In addition to cartilage damage, there
is signiﬁcant synovial pathology in this model, as in human OA. HA treat-
ment of established OA resulted in improved GRF, and our results suggest
this clinical beneﬁt was achieved by modifying synovial pathology. The
effect of HA on synovium was not associated with changes in staining for
the inﬂammatory or pro-ﬁbrotic molecules examined. As cartilage damage
was already established at the time of initiating HA therapy, the change in
the ensuing 10 weeks may have been insufﬁcient to detect a therapeutic
effect. The reduced expression of MMP-13 by HYADD4®-G could limit
continued cartilage erosion. The more prolonged clinical beneﬁt with
HYADD4®-G may be related to its effect on endogenous HA synthesis.
HA preparations such as HYADD4®-G, with increased joint retention and
reduced treatment frequency, may offer advantages in OA treatment.
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Purpose: To clarify whether intraarticular hyaluronan injection is effective
for knee osteoarthritis in hemodialysis patients.
Methods: The subjects were 15 knees of 10 hemodialysis patients,
3 males and 7 females, with symptomatic knee osteoarthritis. Mean
patient age was 63.5 years, range 55 to 82 years. The mean duration of
hemodialysis was 14.7 years, range 10 months to 31 years. There were
3 knees with Kellgren-Laurence (K-L) grade II, 6 with grade III, and 6
with grade IV. Intraarticular injection of hyaluronan (ARTZ Dispo® 25mg,
Kaken Pharmaceutical Co. Ltd., Tokyo, Japan) was performed 5 times per
week. We assessed the visual analogue scale (VAS) of knee pain and the
Japan Knee Osteoarthritis Measure (JKOM) score for evaluation of knee
function. We also analyzed the concentrations of MMP-3, chondroitin
6-sulfate (C6S), chondroitin 4-sulfate (C4S), and hyaluronan in aspired
synovial ﬂuids.
Results: Intraarticular hyaluronan administration reduced the degree of
pain in 11 of 15 knees (73.3%), most markedly in 9 of 12 knees (75%)
with K-L grades III and IV. JKOM scores were improved in 5 of 10 patients
(50%). The concentrations of MMP-3, C6S and C4S were decreased in
5 of 6 knees (83.3%).
Conclusions: Intraarticular hyaluronan injection reduced the degree of
knee pain and improved knee function in hemodialysis patients with knee
osteoarthritis by decreasing the concentrations of MMP-3, C6S and C4S
in synovial ﬂuid.
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Purpose: Vitamin K is a family of structurally similar, fat-soluble,
2-methyl-1,4-naphyhoquinones, including phylloquinone (K1), menaquin-
ones (K2), and menadione (K3). Among these molecules, menaquinones
exerts an inﬂuence on bone building, especially in osteoporosis. This
effect is demonstrated by its ability of posttranscriptional modiﬁcation of
a number of vitamin-K dependent proteins such as osteocalcin or matrix
GLA protein (MGP), a bone protein containing gamma-carboxyglutamic
acid. Our previous study revealed that MGP played a critical role in regu-
lating endochondral chondroctyte maturation and ossiﬁcation processes
by inhibiting cartilage mineralization in vitro and vivo assays. MGP is
not only present in the mineralizing zone of the growth cartilage, but
also present in articular cartilage. Hence, there might be the possibility
that vitamin K inﬂuences physiological or pathological course of articular
cartilage. This study demonstrates the effect of oral administration of
vitamin K2 on the pathological progress of OA using Hartley guinea pigs.
Methods: Hartley strain female guinea pigs (n = 45) were obtained at
4 months of age from Charles River Laboratories (Wilmington, MA).
Animals were divided into 9 groups (n = 5) at random. Food and water
were available ad libitum. One group was harvested at 4 months of age
as control subjects. Eight groups were raised for the subsequent 2, 4,
6, and 8 months with or without food containing vitamin K2 (content
30mg/g). Animals were euthanized by administration of lethal doses of
pentobarbital, and bilateral knee joints were then dissected for following
experiments. The dissected joints were fully exposed by disarticulating
the patella and severing the cruciate ligaments. After application of India
ink, gross morphologic changes of tibial plateau were evaluated. The
gross appearance was judged according to the criteria as described by
Yoshioka et al. Furthermore, the area of ink-retained portion and total
cartilage surface of tibial plateau were calculated in each individual. The
ratio of ink-retained area to total cartilage surface was determined.
Coronal plane sections (5 mm) cut at 200-mm intervals of tibial plateau
were stained with hematoxylin and eosin, and Safranin-O. Histological
scoring of serial sections of each knee was also performed. Histopatho-
logic alterations in the knee joints were graded according to the Mankin
criteria. All sections were graded and median scores were determined for
statistical analysis. All data are expressed as the mean±SD. Statistical
analysis was performed by using the un-paired t-test.
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Results: Progressive histopathologic changes characteristic of devel-
oping OA were observed concomitantly with aging. This change was
initiated by the disruption of the weight-bearing regions of articular
cartilage at 6 months of age, and subsequent changes such as cloning
of chondrocytes or loss of Safranin-O staining were recognized from
8 months of age onward. The ﬁgure shows the Mankin scores obtained
from sections stained with Safranin-O. As shown in this ﬁgure, the scores
were increased with aging in both groups. Statistical signiﬁcance was
recognized between two groups only in the early phase at 6 months
(p = 0.032). This data was consistent with the data of gross appearance.
Conclusions: The present study demonstrated that menaquinones could
delay the progression of osteoarthritis. To our knowledge, this is the ﬁrst
report to discuss the effect of menaquinones on the pathological feature
of OA.
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Purpose: To evaluate the efﬁcacy and tolerability of one single hyaluronic
acid (Adant®) intra articular (IA) injection for hip osteoarthritis (OA).
Methods: A randomised, double-blind (investigator blinded to the proce-
dure), placebo-controlled trial. Patients (age over 30) with symptomatic
hip OA (pain level on VAS >40mm), Kellgren Lawrence grade II or III, were
randomly allocated to receive one ﬂuoroscopically guided IA injection of
hyaluronic acid (2.5ml) or placebo (2.5ml). Patients were followed up
every month for 3 months. The mean outcome measure was the level
of pain recorded on a VAS (0–100mm) at month 3 and compared with
baseline. Secondary outcomes included the percentage of responders
according to the OMERACT-OARSI criteria, the Western Ontario and
McMaster Universities (WOMAC) OA index subscores on pain, stiffness
and disability, the patient’s and physician’s global assessments. Safety
was assessed at each visit. Statistical analysis was performed on the
inter-group difference in the intent-to-treat population (ITT) and in the per
protocol (PP) population. Missing data were replaced by carrying forward
the last outcome.
Results: Eighty-ﬁve patients were included, and were randomized in the
hyaluronic acid group (n = 42) or in the placebo group (n = 43). Baseline
characteristics were similar between the two groups. The number of drops
out was 5% (n=4). At end point, the decrease in pain was −7.8 (24.95)
and −9.12 (27.37) in the hyaluronic acid and placebo groups respectively,
in the ITT population (p = 0.98). Same result was found in PP analysis.
The OMERACT-OARSI responder rate was 33.3% in the hyaluronic acid
group and 32.5% in the placebo group (p = 0.94). There was no signiﬁcant
difference, both in ITT and in PP analysis, in secondary end points as well
as in the consumption of rescue medication between placebo and verum.
There was no difference in the frequency of adverse events between
groups.
Conclusions: This study failed to show a superior symptomatic effect
of a single IA hyaluronic acid injection (Adant®) over placebo in patients
with hip OA. Further studies are required to explore the potential efﬁcacy
of more than one single intra articular injection in hip OA.
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Purpose: Elucidate if a daily common clinical administration of two
intraarticular drugs as Hyaluronic Acid (H.A.) used to treat osteoarthrosis
and Bupivacaine used as local anaesthesia, cause increase degradation
of Hyaluronic Acid.
Methods: In vitro studies with ﬁve commercial H.A. have been used for
this study, (Synvisc®, Coxarthrum®, Go-on®, Hyalgan® and Durolane®)
with Bupivacaine at three different concentrations (0.25%, 0.50% and
0.75%) with/without adrenaline (1/200,000), with 24 hours incubation at
4ºC and 37ºC. Cromatography procedures (molecular exclusion HPLC)
have been used for determination of molecular weight and degradation
percentage of H.A. Anova-Manova and Kendall’s correlation have been
used to determinate statistiscal signiﬁcance.
Results: Synvisc® and Durolane® have shown less degradation and
different behavior than Coxarthrum®, Hyalgan® and Go-on® (Kendall’s
correlation p< 0.05). Temperature of incubation modiﬁed the degradation
of H.A. Durolane® and Synvisc® at 4ºC showed higher degradation
than at 37ºC (p< 0.05), otherwise happens for Coxarthrum®, Go-on®
and Hyalgan® that increased degradation at 37ºC (p< 0.05). Higher
concentration of Bupivacaine increased the degradation of H.A. in all
cases (p< 0.05) and the concomitant use of adrenaline increased the
degradation in the three concentrations used at the present study for
Synvisc®, 0.25 and 0.75 for Coxarthrum®, only at 0.75 for Durolane® and
0.25 for Go-on® (p< 0.05). Adrenaline seems not to increase degradation
over Hyalgan.
Conclusions: Bupivacaine administration (with/without adrenaline) with
H.A. must be valued before concomitant intraarticular administration
because Bupivacaine increased H.A degradation of all the H.A. studied.
Durolane® and Synvisc® have shown less degradation (6 to 20%) and
different behavior than Coxarthrum®, Hyalgan®, Go-on® (12 to 20%, 27
to 29% and 28 to 39% respectively). Higher concentration of Bupivacaine
and the concomitant use of adrenaline increased the degradation of H.A.
in all cases except the concomitant use of adrenaline that seems not to
affect Durolane® degradation except at highest Bupivacaine concentra-
tion.
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Purpose: Chondroitin sulfate (CS) is a SYSADOA eliciting an anti-
inﬂammatory effect. Since patients take CS over long periods, it was
of interest to assess whether CS modulates the activity of cytochrome
P450 isoforms (P450).
Methods: Two models were used, chronic intake of CS in control rabbits
and in rabbits with a down-regulated P450 by an inﬂammatory reaction
(IR). Six groups of 5 rabbits were used; three were used to assess the
effect of CS on P450, one without CS and two receiving orally around
20mg/kg/day CS for 20 and 30 days; three groups received turpentine
s.c. generating an aseptic IR (AIR) 48 h before their sacriﬁce, e.g. days
−2, 18 and 28, exposed to CS for 0, 20 or 30 days, respectively. CYP3A6,
CYP1A2 and NADPH P450 reductase (NADPH) activity, expression and
RNAm were assessed in the hepatocytes.
Results: Compared with control rabbits, 20 and 30 days CS did not affect
the activity of CYP3A6, e.g. 15582±1330, 13480±3052 and 14701±841,
and of CYP1A2, e.g. 6532±1203, 11612±2403 and 7494±746, arbitrary
